Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cyclacel Pharmaceuticals ( (CYCC) ) has provided an announcement.
On July 28, 2025, Cyclacel Pharmaceuticals filed an Amended and Restated Certificate of Designations for its Series F Convertible Preferred Stock, removing the Series F Ownership Limitation. This change allows the stock to be converted and voted without restrictions, potentially impacting the company’s stockholder dynamics and market positioning.
The most recent analyst rating on (CYCC) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Cyclacel Pharmaceuticals stock, see the CYCC Stock Forecast page.
Spark’s Take on CYCC Stock
According to Spark, TipRanks’ AI Analyst, CYCC is a Underperform.
Cyclacel Pharmaceuticals is currently under significant financial strain, marked by operational inefficiencies and a weak financial position, as reflected in its low financial performance score. While the technical indicators suggest a neutral trend, the valuation is unattractive due to its negative P/E ratio and lack of dividend yield. These factors collectively result in a low overall stock score.
To see Spark’s full report on CYCC stock, click here.
More about Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc. is a Delaware-based company operating in the pharmaceutical industry, focusing on developing innovative cancer therapeutics.
Average Trading Volume: 1,861,260
Technical Sentiment Signal: Strong Sell
Current Market Cap: $25.41M
For a thorough assessment of CYCC stock, go to TipRanks’ Stock Analysis page.